Takeda focuses on ‘diverse’ pipeline prospects on heels of two acquisitions
After a whopping $4 billion asset buy from Nimbus Therapeutics, along with a $400 million deal with Hutchmed for a colorectal cancer drug, Takeda executives touted pipeline optimism on its latest earnings call this week.
That’s because the TYK2 inhibitor for psoriasis Takeda is getting from Nimbus, along with the Hutchmed fruquintinib commercialization outside of China, are just two of what it reports are 10 late-stage development programs of promising candidates.
Another of those is its dengue vaccine Qdenga, which notched vaccine approval in the European Union in December, while the US FDA is continuing to review it under priority review. Reviews are ongoing in endemic countries, and the vaccine is already approved in Indonesia as well as Norway, Iceland and the UK.
Livtencity, already approved in the US for post-transplant cytomegalovirus (CMV), got a nod from the EU in November.
CEO Christophe Weber said Takeda is also planning a US submission for TAK-755 to treat the rare disease congenital thrombotic thrombocytopenic purpura (cTTP) this year.
In its mid-pipeline, Weber called out TAK-861 for narcolepsy and TAK-341 in multiple system atrophy, both in Phase II studies.
“We are progressing on our journey to build one of the most exciting and diverse pipelines in the industry,” Weber said.
For its fiscal Q3 year to date, Takeda reported sales of 3.07 billion yen ($23.4 billion), an increase of 13.9% over the same previous period. Entyvio for ulcerative colitis and Crohn’s disease was its top sales earner at 547.9 billion yen ($4.18 billion), and a substantial increase of 38.6% year-over-year